Liminatus Pharma, Inc. Class A Common Stock (LIMN)
NASDAQ
Healthcare
Biotechnology
$0.11
▼ -3.86%
Market Cap
$7.2M
Sector
Healthcare
Industry
Biotechnology
Beta
0.74
52-Wk Range
0.095-4.85
CEO
Chris Kim
Country
US
Currency
USD
Liminatus Pharma, Inc. Class A Common Stock operates in the Biotechnology industry of the Healthcare sector, headquartered in Cerritos, CA, US. The stock last traded at $0.11, down 3.86% on the session, giving a market capitalisation of $7.2M. On trailing twelve-month figures it carries a trailing P/E of -0.26, a net margin of 0.0%. Its beta of 0.74 implies it has historically moved less than the broad market.
Valuation & profitability (TTM)
P/E
-0.26
Price / Sales
0.00
Price / Book
-19.20
EV / EBITDA
-0.62
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
-10.88
Current ratio
0.96
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Select
Employees
1
IPO date
2025-05-01
Headquarters
Cerritos, CA, US
About Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.
Comparable companies
Liminatus Pharma, Inc. Class A Common Stock is most often compared with the following Healthcare names:
More research on LIMN
Open full interactive analysis & DCF →